

# WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 28 janvier 2025 10:01

## LABORATORY INFORMATION

<b>*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:</b>	Paratuberculosis
<b>*Address of laboratory:</b>	ANSES - Laboratoire de Ploufragan-Plouzané-Niort, Unité Pathologie et Bien-Etre des Ruminants, 60 rue de Pied-de-Fond CS28440, 79024 Niort Cedex, FRANCE
<b>*Tel:</b>	+33 (0)5 49.79.61.28
<b>*E-mail address:</b>	virginie.poisson.reseaugds@anses.fr
<b>Website:</b>	
<b>*Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr. Nicolas ETERADOSSI, Head of Ploufragan-Plouzané-Niort Laboratory
<b>*Name (including Title and Position) of WOAH Reference Expert:</b>	Dr. Virginie POISSON, Head of Paratuberculosis thematic
<b>*Which of the following defines your laboratory? Check all that apply:</b>	Governmental

## TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA	Yes	1440	16
Direct diagnostic tests		Nationally	Internationally

**Virginie Poisson - - FRANCE**

Real time PCR	Yes	267	0
Culture	Yes	78	0

## TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
Bovine Standard Serum Paratuberculosis	ELISA	Produced	174 ml	1 ml	2	FRANCE, PORTUGAL,
Diluant for Bovine Standard Serum Paratuberculosis	ELISA	Produced	5 ml		1	FRANCE,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA Members?

No

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

No

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

Name of the WOA Member Country receiving a technical consultancy	Purpose	How the advice was provided
--	---------	-----------------------------

Virginie Poisson - - FRANCE

FRANCE	Paratuberculosis case in zoo : question on interpretation of diagnostic results and advices for the use of diagnostic tests	Phone calls and emails
FRANCE THE NETHERLANDS	Support of kit suppliers for specifications for ELISA serum kits	visioconferences, phone calls and emails

## TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAH Member Countries involved other than your country
RING TRIAL - Application of phage-coated beads to detect viable MAP in feces	April to June 2024	Multi-laboratory evaluation of a novel PhMS-qPCR assay for detecting viable MAP in milk	Confidential	CZECH REPUBLIC FRANCE GERMANY SPAIN UNITED KINGDOM

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAHP?

No

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

Epidemiological data collected during national collection of biological materials

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

Data analysed and presented during French National Professional Reference Day and during French working groups on  
Paratuberculosis

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

1

16th International Colloquium on Paratuberculosis, Vrindavan, India - oral presentation "Paratuberculosis case definition by the WOA" Juste RA, Whittington R, Thibault-Poisson VC, Daptardar M, Garrido JM, Sevilla I, Elguezal N, Alonso M, Chng C, Torres G

c) National conferences:

1

National Professional Reference Day - Maisons-Alfort - 2 février 2024

d) Other (Provide website address or link to appropriate information):

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

No

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025 (06/03/2020 to 31/01/2024)	PDF	ATTESTATION COFRAC - 17025.pdf
ISO 17025 (01/02/2024 to 31/01/2029)	PDF	Attestation_COFRAC.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA - Serum	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Level 2 laboratory and procedures for biorisk management : access control, staff authorization, personal protective equipment,

procedure for waste

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

## TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAHP Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS
Paratuberculosis	Co-organizer with two other labs	3	Argentine, Italian and French Reference laboratories

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOAHP Ref. Labs/ organising WOAHP Ref Lab
Interlaboratory test comparison	participant		FRANCE, ARGENTINA, ITALY (Organiser)

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons <sup>1</sup>	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
Interlaboratory Test	Organizer	1	ELISA Serum	LATVIA,

## Virginie Poisson - - FRANCE

comparison

Interlaboratory Test comparison	Organizer	1	ELISA serum	LITHUANIA,
Mycobacterium avium subsp paratuberculosis antibody detection in serum	Participant	45	ELISA Serum	AUSTRIA, BELGIUM, CZECH REPUBLIC, DENMARK, FRANCE, GERMANY, GREECE, HUNGARY, IRELAND, ITALY, POLAND, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THE NETHERLANDS,
Mycobacterium avium subsp paratuberculosis antibody detection in milk	Participant	33	ELISA Serum	AUSTRIA, BELGIUM, DENMARK, FRANCE, GERMANY, HUNGARY, IRELAND, ISRAEL, ITALY, POLAND, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THE NETHERLANDS, UNITED KINGDOM,
Mycobacterium avium subsp paratuberculosis antibody detection in serum	Participant	45		AUSTRIA, BELGIUM, CZECH REPUBLIC, DENMARK, FRANCE, GERMANY, GREECE, HUNGARY, IRELAND, ITALY, PORTUGAL, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THE NETHERLANDS, UNITED KINGDOM,

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

Kind of consultancy	Location	Subject (facultative)
Participation in Expert Group for Case Définition	videoconferences meetings	Paratuberculosis Case definition

29. Additional comments regarding your report:

Yes

*Carrying out 1 initial controls for the validation of diagnostic kits for ELISA on individual serum.*

*Working on a research project : Study of pathogens (including Map) in post-digestion sample from biogaz digesters*